Amgen Bets $45m Plus Up To $1.7bn On Xencor's Bi-Specifics
This article was originally published in Scrip
Amgen's Blincyto (blinatumumab) was the first US FDA-approved bi-specific antibody and now the biotechnology giant may spend nearly $1.75bn on bi-specifics developed with Xencor Inc.'s XmAb platform for monoclonal antibodies that bind to two separate targets.
You may also be interested in...
At ACR: Janssen reported data that show Celltrion’s Remicade biosimilar is not quite the same, but positive sirukumab results may not boost the Janssen and GSK biologic’s market prospects. Meanwhile, Corbus surged on mid-stage resunab results in systemic sclerosis, Janssen shared Phase II gesulkumab psoriasis results, Genentech eyes a new Actemra indication, and Xencor rose on interim Phase II data.
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.